Renin–angiotensin–aldosterone system (RAAS) blockers (angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB)) are generally used in patients with cardiovascular disease, CKD, and diabetes. Here, ACE is linked to chronic kidney disease.